Notice of Change to Funding Opportunity Description in PAR-15-075 "Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01)"

Notice Number: NOT-CA-15-022

Key Dates
Release Date: July 7, 2015

Related Announcements
PAR-15-075

Issued by
National Cancer Institute (NCI)

Purpose

This Notice amends the following section of PAR-15-075, "Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01)".

The following change to this FOA is being made:

Part 2. Section I. Funding Opportunity Description

Currently reads:

Research projects that are not appropriate for this FOA

This FOA does not support basic research projects that do not emphasize translational processes of adaptation, optimization, and validation for a targeted cancer problem. An application proposing a biological research problem as its essence, (where the technology and methods have already been adapted, optimized, validated and established) is not appropriate for this FOA.

This FOA does not overlap with SBIR/STTR FOAs, e.g., PA-14-071PA-14-072, or PAR-14-088, which apply special restrictions on participants and projects.

Modified to read:

Research projects that are not appropriate for this FOA

This FOA does not support basic research projects that do not emphasize translational processes of adaptation, optimization, and validation for a targeted cancer problem. An application proposing a biological research problem as its essence, (where the technology and methods have already been adapted, optimized, validated and established) is not appropriate for this FOA.

This FOA does not overlap with SBIR/STTR FOAs, e.g., PA-14-071, PA-14-072, or PAR-14-088, which apply special restrictions on participants and projects.

Applications that address in-vivo imaging studies should apply to PAR 13-169 “Academic-Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01)".

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Miguel R. Ossandon, MS
National Cancer Institute (NCI)
Telephone: 240-276-5714
Email: ossandom@mail.nih.gov